Biohaven Pharmaceutical Holding Co Ltd
Biohaven Pharmaceutical — Technical Presentation (May 2019)
35 slides from Biohaven Pharmaceutical's technical presentation, May 8, 2019
Slide 1: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of “safe harbor” provisions of The Private Securities Litigation Reform Act of 1995, including: statements about our plans to develop and commercialize our product candidates, our planned clinical trials for our rime
Slide 2: Neuroinnovating across three novel small-molecule platforms
NEUROINNOVATING ACROSS THREE NOVEL SMALL-MOLECULE PLATFORMS BROAD PIPELINE OF LATE STAGE PRODUCT CANDIDATES
Slide 3: Biohaven's Late Stage Development Pipeline
Biohaven’s Late Stage Development Pipeline RIMEGEPANT Phase 3 Zydis™ ODT Acute Migraine RIMEGEPANT Phase 3 Acute Migraine RIMEGEPANT Phase 3 Long-Term Safety Study CGRP antagonism RIMEGEPANT Phase 3 Preventive Migraine TRORILUZOLE Phase 2/3 Alzheimer’s Disease (AD)† TRORILUZOLE Phase 2/3 Obsessive-C
Slide 4: NOjeCTION CGRP-Antagonist Platform: Expanded Phase 3 Data, Panel Discussion and Q&A
NOjeCTION CGRP-Antagonist Platform TM Expanded Phase 3 Data, Panel Discussion and Q&A Moderator: Kishen Mehta
Slide 5: Richard Lipton, MD
Richard Lipton, MD ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 6 Edwin S. Lowe Professor and Vice Chair of Neurology Professor of Epidemiology and Population Health, Psychiatry and Behavioral Science, Albert Einstein College of Medicine Director, Montefiore Headache Center Fellow, Ameri
Slide 6: David Kudrow, MD
David Kudrow, MD MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 7 Headache Specialist, Board Certified Neurologist - Director, California Medical Clinic for Headache Director Emeritus, Headache Clinic Harbor-UCLA Medical Center Assistant Clinical Professor in Neurology, UCLA David
Slide 7: Jelena Pavlovic, MD, PhD
Jelena Pavlovic, MD, PhD MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 8 Headache specialist, Neurologist, Montefiore Medical Center PhD in Molecular Biology Assistant professor of Neurology, Albert Einstein College of Medicine Board certified in Neurology Member, American Academ
Slide 8: Rimegepant 75 mg Zydis ODT Phase 3 Results in Acute Treatment of Migraine
Rimegepant 75 mg Zydis® ODT Phase 3 Results: Study 303 in the Acute Treatment of Migraine
Slide 9: Study Design: Phase 3 Rimegepant 75 mg Zydis ODT (Study 303)
Study Design: Phase 3 Rimegepant 75 mg Zydis ODT (Study 3031) MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 10 RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT Objective: Assess Rimegepant Zydis ODT versus Placebo on efficacy, safety, and tolerability in the acute treatment of mig
Slide 10: Demographics: Representative of Typical Migraine Patient Population
RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT Demographics: Representative of Typical Migraine Patient Population MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 11 Characteristic Overall (N=1351) Age, years, mean (SD) 40.2 (12.0) Sex, n (%) Female 1147 (84.9) Male 204 (15.1) Mea
Slide 11: Rimegepant Zydis ODT Superiority Over Placebo on Hierarchically-Tested Endpoints
MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 12 Rimegepant Zydis ODT Superiority Over Placebo on 21 Consecutive, Prespecified, Hierarchically-Tested Efficacy Outcome Measures Co-Primary and Secondary Endpoints Rimegepant N=669 Placebo N=682 P value Pain freedom, 2 h (co-primary)
Slide 12: Efficacy Highlights: Single Dose Rimegepant Zydis ODT
RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 13 Efficacy Highlights: Single Dose Rimegepant Zydis ODT Shows Early and Sustained Effects on Pain and Return to Normal Functioning Pain Relief *60 min *90 min *2 hr *24 hr *48 hr Sustai
Slide 13: Nausea Freedom at 2 Hours Post-Dose in Pooled Analysis
RIMEGEPANT PHASE 3 – Studies 301, 302 (75 mg Tablet) & 303 (75 mg Zydis ODT) Nausea Freedom at 2 Hours Post-Dose is Significant in Pooled Analysis 24 hr 48 hr MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 14 Data were analyzed using Cochran-Mantel Haenszel methods. Individual stu
Slide 14: Pain Relief: Early Separation From Placebo
RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT Pain Relief: Rimegepant Zydis ODT Shows Early Separation From Placebo Beginning within 15 Minutes and is Statistically Significant by 60 Minutes MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 1. Pain Relief is defined as patients who
Slide 15: 24-48 hr Pain Relief: Lasting Benefit with a Single Dose
Single Dose of Rimegepant, No Rescue Meds RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT 24-48 hr Pain Relief: Rimegepant Shows Lasting Benefit with a Single Dose Sustained Pain Relief Rimegepant n=669 Placebo n=682 p-value 2 to 24 hrs 47.8% 27.7% <0.0001 3 to 24 hrs 56.4% 33.1% <0.0001 4 to 24 hrs
Slide 16: Pain Freedom: Significant Separation at 2 hrs
RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT Pain Freedom: Rimegepant Demonstrates Significant Separation at 2 hrs and Increasing Benefit Over Time After a Single Dose MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES Single Dose of Rimegepant, No Rescue Meds % of Patients Pain Fr
Slide 17: Rescue Medication Use
RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT Rescue Medication Use: Rimegepant Treated Patients Had Lower Use of Rescue Meds and Delayed Time to Use Data are Kaplan-Meier estimates of Rescue Medicine Use; subjects were censored (not included) at the time of taking rescue medication, and those los
Slide 18: Safety: Rimegepant 75 mg ODT Well Tolerated and Similar to Placebo
RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT Safety: Rimegepant 75 mg ODT was Well Tolerated and Similar to Placebo MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 19 The most common AEs were nausea and urinary tract infection (<1.6%) There were no treatment-related increases in
Slide 19: Summary: Rimegepant 75 mg ODT Profile of Rapid and Sustained Effect
RIMEGEPANT Phase 3 – Study 303, 75 mg ZYDIS ODT Summary: Rimegepant 75 mg ODT – Profile of Rapid and Sustained Effect in the Acute Treatment of Migraine MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 20 Rapid onset of pain relief with single dose Numerical separation from placebo
Slide 20: Rimegepant Value Proposition: "One and Done"
Rimegepant Value Proposition: “One and Done” MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 21 Rapid Pain Relief Zydis® ODT Durable Benefits through 48 hrs Placebo-like Tolerability
Slide 21: Rimegepant 75 mg Open-Label Long-Term Safety Study
Rimegepant 75 mg Open-Label Long-Term Safety Study
Slide 22: Long Term Safety Study 201: Study Design
RIMEGEPANT LONG TERM SAFETY – Study 201 Study Design: Rimegepant 75 mg Open Label Long-Term Safety MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 23 AS-NEEDED up to 52 weeks (up to 1x/daily dosing) FIXED-DOSING up to 12 weeks (QOD+PRN dosing) Observation Period 30 days Rimegepant
Slide 23: Long Term Safety Study 201: Interim Analysis, Overall LFT Results
RIMEGEPANT LONG TERM SAFETY – Study 201, Interim analysis 21FEB2019 MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 24 105,192 doses of rimegepant 75 mg administered across 1,784 patients with migraine Median number of days in study 278 Interim hepatic data were reviewed by an exte
Slide 24: Fixed-Dosing Cohort LFT Results
RIMEGEPANT (BHV-3000) LONG TERM SAFETY STUDY – Study 201, Interim analysis 21FEB2019 MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 25 Subjects in the 12-week QOD+PRN cohort (n=286) were exposed to 11,296 rimegepant 75 mg tablets Median number of tablets per 4 week period 14.2 Med
Slide 25: No Liver Signal Detected in Fixed-Dosing Cohort
RIMEGEPANT LONG TERM SAFETY – Study 201, Interim analysis 21FEB2019, ON-TREATMENT CENTRAL LABS No Liver Signal Detected in Fixed-Dosing (QOD+PRN) Cohort ALT or AST Rimegepant N=286 > 3x ULN 0 > 5x ULN 0 > 10x ULN 0 > 20x ULN 0 Total Bilirubin > 2x ULN 0 Alkaline Phosphatase > 2x ULN 0 LFT Results fr
Slide 26: Rimegepant Shows Reduction in Migraine Days
RIMEGEPANT LONG-TERM SAFETY – Study 201, Interim analysis 21FEB2019 Rimegepant Shows Reduction in Migraine Days All Subjects with > 14 Migraine Days/Mo During Observation Period MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 27 Subjects with > 14 migraine days/mo baseline, show re
Slide 27: Fixed-Dosing Cohort Shows Robust Reduction in Moderate-Severe Migraine Days
48.4% of subjects in the fixed-dosing QOD+PRN cohort experienced >50% reduction from baseline during month 3 in the frequency of monthly migraine days with moderate-to-severe pain intensity RIMEGEPANT LONG TERM SAFETY STUDY – Study 201 Rimegepant Fixed-Dosing Cohort Shows Robust Reduction in Moderat
Slide 28: Prevention Strategy: Redefine the Treatment Paradigm as a Continuum
Prevention Strategy: Redefine the Treatment Paradigm as a Continuum MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 30 Rimegepant acute efficacy and long-duration of action established in three Phase 3 Trials Early signals from 201 data suggest that Rimegepant has the potential for
Slide 29: Clinical Case Reports: Oral Rimegepant for Breakthrough Migraine Attacks in Patients on CGRP mAb
Clinical Case Reports: Use of Oral Rimegepant for Treatment of Breakthrough Migraine Attacks in Patients on CGRP Monoclonal Antibody
Slide 30: Background: Case Reports of Concomitant Use of Oral Rimegepant With CGRP mAb
Background: 2 Case Reports of Concomitant Use of Oral Rimegepant With Injectable CGRP Monoclonal Antibody MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 32 CGRP has been confirmed as a therapeutic target in migraine: While injectable CGRP mAbs have demonstrated efficacy in reducin
Slide 31: Background: Case Reports (Cont'd)
Background: 2 Case Reports of Concomitant Use of Oral Rimegepant With Injectable CGRP Monoclonal Antibody (Cont’d) MAY 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 33 Case reports are presented of 2 patients with historically high migraine frequency participating in the long-term sa
Slide 32: Case Study 1: Rimegepant with Preventive Erenumab
44-year-old white female with a 22-year history of migraine Enrolled in Study 201 (LT Safety) 10 attacks during 1 month run-in Post FDA approval started erenumab (CGRP receptor-targeting mAb) Patient Profile Case Study 1: Oral Rimegepant is Safe and Consistently Effective for Acute Treatment of Brea
Slide 33: Case Study 2: Rimegepant added to Preventive Fremanezumab
47-year-old white female with a 33-year history of migraine On fremanezumab 225 mg/month for 2 months (CGRP ligand-targeting mAb) Enrolled in Study 201 (LT Safety) 11 attacks during 1 month run-in Patient Profile Case Study 2: Oral Rimegepant is Safe and Effective for Acute Treatment of Breakthrough
Slide 34: Summary: Oral Rimegepant in Combination with Injectable CGRP mAbs
Summary: Oral Rimegepant has the Potential to be Safe and Effective at Treating Breakthrough Migraine Attacks in Combination with Injectable CGRP mAbs Conclusions: To our knowledge, these are the first clinical reports showing that oral rimegepant has the potential to be safe and consistently effect
Slide 35: Summary: Oral Rimegepant in Combination with Injectable CGRP mAbs
Summary: Oral Rimegepant has the Potential to be Safe and Effective at Treating Breakthrough Migraine Attacks in Combination with Injectable CGRP mAbs Conclusions: + To our knowledge, these are the first clinical reports showing that oral rimegepant has the potential to be safe and consistently effe
Biohaven Pharmaceutical Holding — Technical Presentation (May 2019) on 6ix